Between March 2020-July 2022, for 651 patients (362 [56%] cases and 289 [44%] controls), where data were available, a higher proportion of cases than controls had impairment in ADLs (199 [68.9%] vs 101 [51.8%], OR [95%CI] 2.01 [1.40-2.98]) and reported symptoms impacting employment (159 [58.2%] vs 69 [35.6%], OR 2.53 [1.72-3.71]). There was no significant difference in depression or anxiety between overall. For cases, impairment of ADLs was associated with increased risk in females, age >50 years and hypertension (OR 5.43 [1.79-16.96], 3.11 [1.17-8.26], and 3.67 [1.06-12.68]). Those receiving either statins or angiotensin converting enzyme inhibitors had a lower risk (OR 0.09 [0.03-0.37], and 0.17 [0.03-0.84]; AUROC 0.794 [0.71-0.88]).